Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. - Wikidata - wikimedia - TriplyDB

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.

http://www.wikidata.org/entity/Q34107482

about

Therapeutic Value of Voltage-Gated Sodium Channel Inhibitors in Breast, Colorectal, and Prostate Cancer: A Systematic Review Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy Epigenetic modulators as therapeutic targets in prostate cancer Valproic Acid Increases CD133 Positive Cells that Show Low Sensitivity to Cytostatics in Neuroblastoma Sodium channel-inhibiting drugs and cancer survival: protocol for a cohort study using the CPRD primary care database Valproic acid as a potential inhibitor of Plasmodium falciparum histone deacetylase 1 (PfHDAC1): an in silico approach.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression.Sodium channel-inhibiting drugs and survival of breast, colon and prostate cancer: a population-based study Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.Emerging role of epigenetics in systemic sclerosis pathogenesis.Histone deacetylases function as a novel potential therapeutic target for cancer.Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.

P2860

Q26772803-EF177E00-C4DD-457F-836F-C833D1FEF7D0 Q26777144-7A3C11AF-A58A-46D1-9E61-4153A4C2EAD4 Q28071912-34BEF84B-D169-4BF7-A5CE-EAE7B9DFEC73 Q28554068-48450C9B-D3A3-492B-B8A9-73161FE065D9 Q28595847-2D5E37B6-E704-494D-AEF3-C895BE6029DC Q35139158-3C5A8B3E-4578-42DF-837F-28918FDDEEDE Q35214924-3F7D11D8-855A-43C9-B088-07265C030CE3 Q35857477-5FBE9C25-C8F8-42C9-879A-3833E1A9DD7D Q36291060-F647CA2D-49C6-4C8F-A9CF-1A2DEBBA539C Q37629548-65B367E5-04D0-49BB-A257-AA8C18801F1F Q38230244-C9E6C01A-6242-4FA7-A2AD-157F036130A2 Q38908331-8640A151-2B8B-4817-9D91-A38D62AA05D3 Q39220891-06EC1AF6-2E78-4A68-92A6-5FD012A53DE3 Q46038047-5088FCBC-54A4-4EE4-9E99-39D3869BDDE5

P2860

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.

http://www.wikidata.org/entity/Q34107482

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phase I study of anti-VEGF mon ...... atients with advanced cancers.

@ast

Phase I study of anti-VEGF mon ...... atients with advanced cancers.

@en

Phase I study of anti-VEGF mon ...... atients with advanced cancers.

@nl

type

label

Phase I study of anti-VEGF mon ...... atients with advanced cancers.

@ast

Phase I study of anti-VEGF mon ...... atients with advanced cancers.

@en

Phase I study of anti-VEGF mon ...... atients with advanced cancers.

@nl

prefLabel

Phase I study of anti-VEGF mon ...... atients with advanced cancers.

@ast

Phase I study of anti-VEGF mon ...... atients with advanced cancers.

@en

Phase I study of anti-VEGF mon ...... atients with advanced cancers.

@nl

P1433

Q34107482-B516A040-3D15-45D7-A581-3E9C56C02D70

P1476

Q34107482-80679986-2D0C-4633-A261-DA47BD0BFA13

P2093

Q34107482-1A0E7609-640A-4178-A4FE-FA8E331CAD7D

Q34107482-22E09E20-FE9E-4FDE-9A7C-47EBCF0BFF6C

Q34107482-67F74D0D-A651-419E-BD85-83ABE76B1599

Q34107482-8A8DD905-DE07-4484-8927-F2C727F01CD7

Q34107482-9F188460-6D0A-4908-8346-36EFD7E060E5

Q34107482-A00683E0-16B3-4D6E-A117-3363955044BC

Q34107482-A5FDA126-AEA5-4327-8874-DFA89790B3C4

Q34107482-D34B217E-BA79-4DA0-9543-E5CECFA99077

Q34107482-EC614E99-AFC8-47E2-BA37-79B59BF9DD55

Q34107482-F1656DE9-BE80-4A53-93A9-29CECDD6C633

P2860

Q34107482-0505574B-3A40-4A7A-9657-F8EC2FDC296E

Q34107482-13E5042A-A894-43FC-9B68-5E67EF7128AC

Q34107482-15739392-B4B4-4AE0-9DF7-85290A3EDC21

Q34107482-18F51A90-61F7-4C58-82FF-CED7A57E16A6

Q34107482-1E73D6CD-128B-4A70-989C-910C164635B1

Q34107482-28245C5A-9B86-4211-80A2-8C2EFB9DD323

Q34107482-39F46449-D38E-4DAB-BABA-77D93708AB46

Q34107482-3CBD2EBE-2FA8-4FC3-AC82-D2CEC397C3BF

Q34107482-54739D36-7D51-4F19-9522-45453422A455

Q34107482-68047DD3-C48C-4981-A0FE-1362C7A282C5

P2888

Q34107482-03095643-3D26-49F7-82A5-5E6B0E83158B

P304

Q34107482-6C0BF915-7D7A-4251-8929-9ECDB94F87FC

P31

Q34107482-571CE099-0B7B-4456-B443-890B488BB4A8

P356

Q34107482-CA9D84AE-F057-4B18-866B-10A7CC2E9B03

P433

Q34107482-9A2F84CA-83F6-42F5-BB45-BD1075B1636F

P478

Q34107482-C1AF87FD-BA6A-4BD6-859B-D05B5DD39A2C

P50

Q34107482-535CE3B7-4E76-41D6-BF1F-7066DDB5B861

Q34107482-9396423F-9925-43C1-A221-3BE6E5B6B910

Q34107482-ED656551-619A-4F8B-A897-2CF7D724B2C2

Q34107482-F5FD81FE-2C3B-4652-886F-7925E08A22B5

P577

Q34107482-B7B33CB9-E310-4806-944B-CB95841AE449

P6179

Q34107482-A22825B3-F82F-4783-AC7A-7A5B79C6A317

P698

Q34107482-2DF28EEE-601D-47F3-BC8E-3E4352C5E0B6

P921

Q34107482-22618347-D7E4-4C27-8D99-E262FD64EAD7

Q34107482-BDB7CB9C-7DDD-44AB-A3AD-1B6DA83DF70C

P932

Q34107482-C25FAB3D-5EF1-4D53-B5A7-2D574AE122D7

P356

S00280-014-2384-1

P1433

Cancer Chemotherapy and Pharmacology

P1476

Phase I study of anti-VEGF mon ...... atients with advanced cancers.

@en

P2093

Apostalia M Tsimberidou

http://www.w3.org/2001/XMLSchema#string

David S Hong

http://www.w3.org/2001/XMLSchema#string

Gerald S Falchook

http://www.w3.org/2001/XMLSchema#string

Hui Yang

http://www.w3.org/2001/XMLSchema#string

Jennifer J Wheler

http://www.w3.org/2001/XMLSchema#string

Johnique T Atkins

http://www.w3.org/2001/XMLSchema#string

Sarina A Piha-Paul

http://www.w3.org/2001/XMLSchema#string

Siqing Fu

http://www.w3.org/2001/XMLSchema#string

Stacy L Moulder

http://www.w3.org/2001/XMLSchema#string

Tiffiny L Jackson

http://www.w3.org/2001/XMLSchema#string

P2860

Nonparametric Estimation from Incomplete Observations

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Vascular endothelial growth factor (VEGF) and its receptors

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

P2888

s00280-014-2384-1

P304

495-501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-014-2384-1

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

Guillermo Garcia-Manero

P577

2014-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024134410

http://www.w3.org/2001/XMLSchema#string

P698

24435060

http://www.w3.org/2001/XMLSchema#string

P921

P932

4148903

http://www.w3.org/2001/XMLSchema#string